

The epidemiology of neuropathic pain: an analysis of prevalence and associated factors in UK Biobank

Georgios Baskozos^{1†}, Harry L Hébert^{2†}, Mathilde M V Pascal¹, Andreas C. Themistocleous¹, Gary J Macfarlane³, David Wynick^{4*}, David L H Bennett^{1*}, Blair H Smith^{2*}

¹Neural Injury Group, Nuffield Department of Clinical Neuroscience, John Radcliffe Hospital, University of Oxford, Oxford, UK

²Chronic Pain Research Group, Division of Population Health and Genomics, Mackenzie Building, Ninewells Hospital & Medical School, University of Dundee, Dundee, UK

³Epidemiology Group and Aberdeen Centre for Arthritis and Musculoskeletal Health, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK

⁴Bristol Medical School, University of Bristol, Bristol, UK

† Joint first authors

* Joint senior authors

Pages: 17

Tables: 0

Figures: 9

Joint corresponding authors: Dr Georgios Baskozos^a and Dr Harry L. Hébert^b

^aAddress: Nuffield Department of Clinical Neuroscience, Level 6 West Wing, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK

Tel:

Email: georgios.baskozos@ndcn.ox.ac.uk

URL: <https://www.ndcn.ox.ac.uk/team/georgios-baskozos>

^bAddress: Division of Population Health and Genomics, Mackenzie Building, Ninewells Hospital & Medical School, University of Dundee, Dundee, DD2 4BF, UK

Tel: +44 (0)1382 383191

Email: h.hebert@dundee.ac.uk

URL: <https://discovery.dundee.ac.uk/en/persons/harry-hebert>

Abstract

1 Previous epidemiological studies of neuropathic pain have reported a range of prevalences and
2 factors associated with the disorder. This study aimed to verify these characteristics in a large UK
3 cohort. A cross sectional analysis was conducted of 148,828 UK Biobank participants who completed
4 a detailed questionnaire on chronic pain. The *Douleur Neuropathique en Quatre Questions* (DN4)
5 was used to distinguish between neuropathic pain (NeuP) and non-neuropathic pain (Non-NeuP) in
6 participants with pain of at least 3 months' duration. Participants were also identified with less than
7 3 months' pain or without pain (NoCP). Binomial and multinomial regression were used to identify
8 factors associated with NeuP compared to Non-NeuP and NoCP respectively. Chronic pain was
9 present in 76,095 participants (51.1%). The overall prevalence of NeuP was 9.2% (13,744/148,828).
10 NeuP was significantly associated with worse health-related quality of life, having a manual or
11 personal service type occupation and younger age compared to NoCP. As expected NeuP was
12 associated with diabetes and neuropathy, but also other pains (pelvic, post-surgical and migraine)
13 and musculoskeletal disorders (rheumatoid arthritis, osteoarthritis and fibromyalgia). Additionally,
14 NeuP was associated with pain in the limbs and greater pain intensity and higher BMI compared to
15 Non-NeuP. Female gender was associated with NeuP when compared to NoCP, whilst male gender
16 was associated with NeuP when compared to Non-NeuP. This is the largest epidemiological study of
17 neuropathic pain to date. The results confirm that the disorder is common in the general population
18 and is associated with a higher health impact than non-neuropathic pain.

19 **Keywords:** Neuropathic pain, general population, prevalence, risk factors, UK Biobank, epidemiology

1. Introduction

1 Chronic pain, usually defined as pain lasting for three months or more [53], is the leading cause of
2 disability worldwide, when all pain conditions are taken into account, including low back pain,
3 headache disorders and neck pain [23]. Neuropathic pain (NeuP) is a particularly severe form of
4 chronic pain, arising as a direct consequence of a lesion or disease effecting the somatosensory
5 nervous system [52]. Examples of common causes of NeuP include diabetes, HIV and chemotherapy
6 treatment for cancer (causing painful peripheral neuropathies), herpes zoster (causing postherpetic
7 neuralgia), multiple sclerosis, surgery, stroke and spinal cord injury [12]. NeuP is likely to be a major
8 contributor to the global burden of chronic pain [7].

9 From a clinician's perspective, it is important to distinguish NeuP from other forms of pain, for
10 example nociceptive pain, which arises from actual or threatened damage to non-neural peripheral
11 tissue. NeuP is generally unresponsive to analgesics such as non-steroidal anti-inflammatory drugs
12 (NSAIDs) or opioids. Rather gabapentinoids (gabapentin and pregabalin), tricyclic antidepressants
13 (TCAs) and serotonin-norepinephrine reuptake inhibitors (SNRIs; duloxetine and venlafaxine) are
14 recommended as first- and second-line treatments [18]. Nonetheless, these medications for NeuP
15 provide greater than 50% pain relief in less than half of people treated. Furthermore, analgesics in
16 general, particularly opioids and gabapentinoids, can potentially cause harm, providing an even
17 greater emphasis on appropriate use [26].

18 In order to identify NeuP in the community and the general population, screening tools such as the
19 *Douleur Neuropathique en Quatre Questions* (DN4) [8], Self-Administered Leeds Assessment of
20 Neuropathic Symptoms and Signs (S-LANSS) [5] and the painDETECT [20] have been developed.
21 These rely on typical symptoms experienced in NeuP including burning, electric shocks, pins and
22 needles and tingling. This has allowed epidemiological studies to be conducted. Estimates of NeuP in
23 the general population suggest the prevalence is 7-10% [28], increasing to around 20-30% in people
24 with diabetes [1,2,10,13]. Previous studies have also reported greater prevalence of NeuP, as with
25 chronic pain overall, in older people, women and people from areas of high social deprivation [43].

26 However, due to differences in screening tools used and sample selection biases between studies,
27 there is a large amount of heterogeneity in findings. For example, in Hong Kong the reported
28 prevalence of NeuP was 5.1% using the Identification Pain Questionnaire [60], whereas in Kuwait it
29 was 17.8% using the DN4 [62]. Furthermore, whilst a Canadian study reported a significantly
30 increased risk of NeuP in males [54], other studies have reported an increased risk in females [9,50].
31 Reliable information on NeuP prevalence and associated factors in the general population are vital
32 for developing prevention and management strategies. The UK Biobank has recently re-phenotyped
33 participants for chronic pain, creating, to the best of our knowledge, the largest available cohort for
34 the study of pain, including NeuP. The size and scale of this cohort provides an ideal platform with
35 which to validate the findings of previous studies and identify novel associations.

36 The aim of this study was therefore to describe the epidemiology and clinical characteristics of NeuP
37 in the UK Biobank.

2. Methods

1 This study is reported using the Strengthening the Reporting of Observational Studies in
2 Epidemiology (STROBE) guidelines for cross-sectional studies (Supplementary Table 1).

3

2.1. Dataset

4 2.1.1. The UK Biobank cohort

5 UK Biobank comprises 501,518 volunteers recruited between 2006-10 (at ages 40-69 years) from
6 across Great Britain. It consists of demographic and health data as well as linked bio-samples and
7 specialist investigations such as imaging in subgroups [46]. A brief assessment of Chronic pain was
8 completed by all participants at first assessment
9 (<http://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=6159>) though it did not include validated
10 questionnaires enabling categorisation of chronic pain and differentiation of NeuP from non-
11 neuropathic pain (non-NeuP). The authors BS, DB, DW and GJM participated in the design of a set of
12 revised UK Biobank pain questionnaires [6] between 2017 and 2018. This was tailored to UK Biobank
13 and based on validated questionnaires already in routine use and as far as possible aligned with
14 established international consortia studying chronic pain such as Generation Scotland [41,42] and
15 DOLORisk [27,40]. These were designed to focus on the most prevalent causes of chronic pain and
16 associated comorbidities and risk factors, including: musculoskeletal pain, NeuP and headache. The
17 choice of items to include for NeuP was based on international recommendations made for
18 phenotyping in genetic studies [29].

19 2.1.2. Re-phenotyping for neuropathic pain

20 Once approved by the UK Biobank scientific panel, a successful pilot test of 10,000 participants was
21 undertaken in April 2019. The chronic pain phenotyping survey was then sent to all currently active
22 UK Biobank participants in May 2019 who had consented to further electronic contact and had an
23 active email address (n=335,587). This has been completed by 167,203 individuals.

24 The revised follow up UK Biobank pain questionnaires first asked about medical history, based on a
25 list of conditions that commonly lead to chronic pain. These included musculoskeletal conditions
26 such as osteoarthritis and rheumatoid arthritis but also important aetiological factors for NeuP such
27 as diabetes, nerve damage, neuropathy and post-herpetic neuralgia.

28 Participants were asked to indicate if they had been suffering from pain for more than three months
29 (defined as chronic pain [53]); if yes, they were asked if they experienced pain all over the body and
30 if they answered yes they were asked to report pain intensity on average over the previous 24 hours
31 on an 11-point visual analogue scale (VAS; 0 being no pain, 10 the worst possible pain) and directed
32 to part one of the ACR questionnaire for preliminary diagnostic criteria for fibromyalgia [59]. If they
33 did not experience pain all over the body they were directed to a list of body sites, where they
34 indicated all the locations in which they had experienced pain in the previous three months. They
35 also rated the pain intensity at each location over the last 24 hours, on an 11-point visual analogue
36 scale (VAS; 0 being no pain, 10 the worst possible pain). They then identified which of these pains
37 had bothered them most during the previous three months. As many people with chronic pain have
38 multiple pain conditions, the subsequent pain-related questionnaires asked the participants to

1 complete them with regard to their most bothersome pain. To assess the quality of their pain,
2 participants completed the self-reported items on the *Douleur Neuropathique en Quatre Questions*
3 (DN4) questionnaire which is a validated tool for NeuP screening based on pain quality [8]. The
4 characteristics of the most bothersome pain were captured with bespoke questions based on the
5 Brief Pain Inventory (BPI) – Short Form [11], asking about pain intensity over the previous 24 hours
6 and on average. Participants were asked to rate the relief they obtained from pain medication, and
7 how their pain impacted different areas of their lives (e.g. general activity, mood, sleep).

8 The EQ-5D-5L[30] was used to ask about health-related quality of life in more detail; this included a
9 0-100 VAS, where the participants were asked to select the number that best represented their
10 health at that time, and an assessment of the extent of limitations experienced in different domains
11 of life (mobility, self-care, usual activities, pain or discomfort, and anxiety and depression).

12 The presence of peripheral neuropathy in the legs and feet was assessed with the self-complete
13 component of the Michigan Neuropathy Screening Instrument (MNSI) [16], for those participants
14 who answered yes to the presence of at least one of the following in the medical history section:
15 cancer pain, diabetes or nerve damage other than diabetic neuropathy. These conditions are
16 common causes of length-dependent peripheral neuropathy, and symptoms are expected to be
17 present distally. Finally, participants were asked to complete psychosocial questionnaires about
18 depression (Patient Health Questionnaire-9, PHQ-9 [35]) and fatigue (Fatigue Severity Scale, FSS
19 [36]).

20 Body Mass Index (BMI) was calculated from height and weight data measured during the initial
21 Assessment Centre visit in 2006-2010. Ethnic background, job and current employment status were
22 also collected during the initial Assessment Centre visit using the UK Biobank touchscreen
23 questionnaire. Age of participants at the time of completion of the pain phenotyping questionnaires
24 was calculated from the year of birth, collected at recruitement, and the time the questionnaires
25 were completed. Index of Multiple Deprivation was calculated using distinct domain of deprivations
26 that can be recognised and measured separately and were collected during the Initial Assessment
27 visit. Main diagnosis was obtained from the summary field of the distinct primary diagnosis, coded
28 using the International Classification of Diseases (ICD-10), which were recorded from the
29 participants hospital inpatient record during 2013-2022. Full background information about the
30 follow-up UK Biobank pain questionnaire, and the questions included is available at
31 https://biobank.ctsu.ox.ac.uk/crystal/ukb/docs/pain_questionnaire.pdf.

32 For analysing this study, we divided the cohort into three groups:

- 33 1) Chronic neuropathic pain (NeuP): participants who reported having pain for more than three
34 months AND who scored 3 or more on the DN4, N = 13,744
 - 35 2) Chronic non-neuropathic pain (Non-NeuP): participants who reported having pain for more
36 than three months AND who scored less than 3 on the DN4, N = 62,351
 - 37 3) No chronic pain (NoCP): participants who did not report having pain, OR whose reported
38 pain had lasted less than three months, N = 72,733
- 39 Only fully completed DN4 questionnaires were considered for group allocation. Chronic pain
40 participants with an incomplete DN4 were not classified.

41

2.2. Statistical analysis

1 Data was collected electronically by completion of a structured online questionnaire. As non-white
2 ethnic backgrounds were rare in UK Biobank (2.2%), we grouped together all Black, Asian and
3 Minority ethnicities (BAME) into one group. Of the total UK Biobank cohort, 1.6% were BAME, 0.6%
4 were mixed ethnicity and the remaining 97.8% were white.

5 Occupations were encoded according to the Departments of National Statistics Standard
6 Occupational Classification (SOC 2000) major groups. The Index of Multiple Deprivation, a weighted
7 composite score showing relative deprivation, i.e. the higher the score the more deprived the
8 individual, was used as a measure of poverty.

9 In order to determine differences between groups we carried out omnibus tests: one-way ANOVAs
10 for normally distributed data or the Kruskal Wallis test for non-parametric data. These were followed
11 up with Tukey's HSD post-hoc tests. Associations between groups and categorical variables were
12 tested using the Chi-Square test. Significant associations were followed up by pairwise Bonferroni
13 corrected chi-square post-hoc tests, the standardised residuals showing higher or lower than
14 expected ratios and the associated p.values are shown in supplementary figures. Univariable tests
15 were followed by multivariable modelling with binomial or multinomial, multiple logit regression
16 depending on the number of levels of the dependent variable. In multivariable modelling, missing
17 values were imputed in 20 cycles of multiple imputations by chained equations using the predictive
18 mean matching algorithm. Before model fitting, we removed variables with >30% missing values,
19 variables with low variance, the least informative variable (i.e. lower variance) from highly correlated
20 pairs (Pearson's correlation coefficient >0.8) or those directly measuring pain. Missing value
21 percentages for all variables are in supplementary table 2. In multivariable modelling we used the
22 outcome as the dependent variable and a set of uncorrelated independent variables that included
23 the self-reported quality of life measured by the EQ5D index, sex, age, ethnic background, job, index
24 of multiple deprivations, the 3 first principal components of genetic variation and binary tags for
25 self-reported diseases: Diabetes, Other Neuropathy, Fibromyalgia, Chronic Fatigue Syndrome,
26 Osteoarthritis, Rheumatoid arthritis, Cancer pain, Carpal Tunnel Syndrome, Complex Regional Pain
27 Syndrome, Chronic post-surgical pain, Gout, Migraine, Pelvic pain. The genetic variation principal
28 component loadings were downloaded from UK Biobank and were calculated by PCA analysis on
29 101284 SNPs.

30 Model coefficients were aggregated across imputations using Rubin's rules. For the significant model
31 coefficients (one-way ANOVA p.value <0.05), we present exponentiated aggregate model coefficient
32 estimations and the associated 95% confidence intervals.

3. Results

3.1. Demographics and socio-economic status

1 167,203 participants completed the pain experience phenotyping (response rate 49.8%). There was
2 an over-representation of participants who were female, of younger age, lower BMI and less socially
3 deprived in the group that chose to complete the pain re-phenotyping questionnaire compared to
4 the rest of the UK Biobank cohort who did not complete the pain phenotyping, regardless of
5 whether they were sent a questionnaire, supplementary table 3. 148,828 out of the 167,203 (89%)
6 participants had no chronic pain or chronic pain with a fully completed DN4 questionnaire, which
7 can be used as a screening tool for NeuP (see methods). The participants with completed DN4 had
8 the same deprivation levels as those that had not completed the questionnaire, but there were
9 more females, of slightly higher age and higher BMI than the participants with incomplete DN4,
10 supplementary table 4. 13,744 participants reported chronic NeuP; 62,351 participants reported
11 chronic Non-NeuP; 72,733 participants reported no chronic pain. The prevalence of NeuP in this
12 cross-sectional cohort was therefore 9.2% (13734/148828). Age and sex were significantly
13 associated with outcome (p.value < 0.001): participants with NeuP were younger than those with
14 Non-NeuP (p.value <0.01, means difference -0.33, 95%CI[-0.5, -0.16]), figure 1A and supplementary
15 figure 1A. Participants who reported chronic pain, both Neuropathic (NeuP) and Non-Neuropathic
16 (Non-NeuP), were more likely to be female than those participants without chronic pain (59% vs
17 52%, p.value < 0.001), figure 1B and supplementary figure 1B. Ethnic background was significantly
18 associated with outcome (p.value < 0.001), figure 1C. 90.7% of participants with NeuP were white
19 British; in the total UK Biobank cohort 97.8% of participants were white British. There was a higher
20 proportion of whites in the Non-NeuP (98.34%) vs the other groups, while BAME were more likely to
21 report NoCP and NeuP (1.58%) versus Non-NeuP (1.19%), , supplementary figure 1C. BMI was
22 significantly associated with pain grouping (p.value <0.001): BMI was significantly higher in
23 participants with NeuP vs Non-NeuP (p.value <0.01, means difference 1.14, 95%CI[1.04, 1.23]) and in
24 participants with Non-NeuP vs NoCP (p.value <0.01, means difference 1.86, 95%CI[1.76, 1.96]),
25 supplementary figure 1D. Both employment status and occupation/job type were significantly
26 associated with the outcome (p.value < 0.001). People with NeuP were more likely to report that
27 they were “Unable to work because of sickness or disability” compared to those with Non-NeuP
28 and NoCP, figure 2A and supplementary figure 2A. People with NeuP were more likely to work in
29 “Elementary occupations”- simple and routine tasks, involving the use of hand-held tools and in
30 some cases considerable physical effort; “Process, plant and machine operatives” - operate and
31 monitor large scale, and often highly automated, industrial machinery and equipment; and “Personal
32 service occupations” compared with the other two groups, figure 2B and supplementary figure 2B.
33 The multiple deprivation index was significantly associated with the outcome (p.value < 0.001) and
34 was higher (consistent with increased deprivation), in people with NeuP vs Non-NeuP (p.value <0.01,
35 means difference 2.04, 95%CI[1.76, 2.32]) and in NeuP vs NoCP (p.value <0.01, means difference
36 2.34, 95%CI[2.06, 2.61]). It was also slightly higher in and Non-NeuP vs NoCP (p.value < 0.01, means
37 difference 0.3, 95%CI[0.14, 0.46]), supplementary figure 2C.

38

3.2. Pain rating and quality of life

1 People with NeuP reported higher pain severity ratings for the self-reported most bothersome pain
2 (p.value <0.001), figure 3A. The most bothersome pain in people with NeuP was reported to be in
3 the feet, hands or legs was more frequently; whereas reporting the most bothersome pain was
4 reported to be in the back, hip, knee, stomach, abdomen or head most frequently by people with
5 Non-NeuP, figure 3B. The quality of life as measured by the EQ5D normalised index was dependent
6 on outcome (p.value < 0.001) and was significantly lower (p.value <0.01) in people with NeuP vs
7 NoCP (means difference -0.22, 95%CI[-0.23, -0.22]) and Non-NeuP vs NoCP (means difference -0.14,
8 95%CI[-0.14, -0.14]), figure 4A and supplementary figure 3. The association between NeuP and
9 reduced quality of life was consistent across all body locations figure 4B. People with NeuP were
10 more likely to have “Diseases of the nervous system” than by both the other groups and “Certain
11 infectious and parasitic diseases” than people with NoCP, figure 5 and supplementary figure 4.

12 Focusing on people with chronic pain (both NeuP and Non-NeuP), we observed that DN4 scores
13 were significantly associated with the pain severity rating and were higher for participants with
14 higher pain ratings for the most bothersome pain, figure 6A (p.value < 0.001). The highest DN4
15 scores were those of participants with the most bothersome pain in the feet and legs, followed by
16 hands and face, figure 6B. People with pain in both feet had significantly higher DN4 scores than
17 people with pain only in one foot (p.value < 0.001), figure 6C. Pain severity ratings for the most
18 bothersome location were higher in participants with higher BMI scores (figure 7A), lower quality of
19 life (figure 7B), and/or who were unable to work due to sickness or disability (figure 7C) and slightly
20 higher for among participants with higher deprivation scores (figure 7D).

21

3.3. Multivariable modelling

22 In figure 8 and supplementary table 5 we present the exponentiated coefficients/odds ratios (ORs)
23 for all terms that reached significance (one-way ANOVA $p < 0.05$) for the multinomial model with a
24 three-level dependent variable considering no chronic pain as the reference condition. Both NeuP
25 and non-neuP were strongly associated with having lower QoL (assessed using EQ5D in which a
26 higher score reflects a higher quality of life) The presence of diabetes increased the odds ratio for
27 NeuP and decreased them for Non-NeuP. All other self-reported conditions increased the odds ratios
28 for both NeuP and Non-NeuP but had a larger effect for NeuP. Males had lower odds ratio for both
29 NeuP and Non-NeuP. In addition those who held “Associate Professional and Technical Occupations”
30 or were “Managers and Senior Officials” were more likely to report Non-NeuP. “Associate
31 Professional and Technical Occupations”, “Process, Plant and Machine Operatives” and “Skilled
32 Trades Occupations” increased the odds for NeuP, while “Professional Occupations” decreased the
33 odds for NeuP.

34 In figure 9 and supplementary table 6 we present the ORs for a binomial model with a two-level
35 dependent variable, NeuP versus Non-NeuP. Male participants had a higher OR for NeuP vs Non-
36 NeuP. Higher BMI and lower age were associated with an increased OR for NeuP. Most bothersome
37 pain in the feet was associated with an increased OR for NeuP, whereas most bothersome pain in
38 the abdomen, shoulder, knee, hip. Back, chest and headache was associated with reduced OR for
39 NeuP. “Personal Service Occupations” was associated with increased OR for NeuP and “Professional
40 Occupations” with decreased OR for NeuP.

4. Discussion

4.1. Summary

1 In this large cross-sectional study of middle-aged adults in UK Biobank, the prevalence of NeuP was
2 9.2%, making up 18.1% of those with chronic pain. After adjusting for confounding variables, factors
3 associated with NeuP compared to NoCP were worse health-related quality of life, increased social
4 deprivation, having manual or personal service type occupations, not having a professional
5 occupation and younger age. These factors were also associated with NeuP compared to non-NeuP,
6 as were pain in the upper and lower extremities, worse pain location intensities and higher BMI.
7 Female sex was associated with NeuP compared to NoCP, but male sex was associated with NeuP
8 compared to non-NeuP. NeuP co-morbidities included expected associations such as neuropathy and
9 diabetes but also other pain (pelvic pain, migraine and post-surgical pain) and musculoskeletal
10 disorders (rheumatoid arthritis, osteoarthritis and fibromyalgia).

11

4.2. Interpretation

12 The published range of prevalence estimates for NeuP in the general population is 3.2-17.9%
13 [9,14,25,32,38,51,54,60–62]. In the UK, two studies reported a prevalence of 8.2% [50] and 9.3%
14 [48] respectively. These two figures are similar to the current study (9.2%). It should be noted
15 though that these studies did not cover Wales or Northern Ireland and the current study did not
16 cover Northern Ireland. The wide range of prevalences reported is partly due to differences in case
17 ascertainment and definition. In Japan, the relatively low prevalence of 3.2% can be explained by the
18 stringent case definition used, which included a longer duration of pain (6 months compared to 3
19 months) and pain intensity of 5 or more out of 10 [32]. In studies that used the same definition as
20 the current one, the prevalence of NeuP was lower in France (6.9%; [9]) and higher in Canada (16.1%
21 and 17.9%; [51,54]) and Morocco (10.6%; [25]), though these studies have a wider age range than
22 the current study, which is predominantly middle and older aged.

23 The current study has enabled the identification of associations with a greater level of precision than
24 previous studies. First, people with NeuP have worse health-related quality of life than people
25 without NeuP [3,32,49,51]. Most of the studies reporting this finding used only univariate hypothesis
26 tests, i.e. considering only one variable at the time, which does not take potential confounding
27 factors into account, such as differing pain intensity [38,62], in contrast to the current study.

28 Second, this study supports previous findings that pain intensity is more severe in people with NeuP
29 than people with non-NeuP [9,25,32,38,48,50,51,60,62]. Part of the possible reason for this is the
30 relative difficulty in treating NeuP. It has previously been reported that significantly fewer people
31 with NeuP rate their prescribed treatment (medication or other forms of therapy) as “very
32 successful” [60].

33 Third, people with NeuP were more likely to report pain in their hands, legs or feet [9,25,32,50,62],
34 whilst people with non-NeuP were more likely to report pain in their stomach or abdomen, neck or
35 shoulder, knees, hips, head, chest and back [25,50,62]. Common aetiologies of NeuP including
36 diabetes, surgery, carpal tunnel syndrome, complex regional pain syndrome and cancer often affect
37 the upper and lower extremities. This is supported by the association of these comorbidities
38 independently with NeuP.

1 In addition to these findings, we identified some novel associations with NeuP in the general
2 population. This includes rheumatoid arthritis. Whilst arthritis is generally considered to be non-
3 neuropathic in nature, there is growing evidence of a neuropathic component to this cause of pain
4 [17,33,34,45]. Furthermore, rheumatoid arthritis can predispose to NeuP disorders such as carpal
5 tunnel syndrome [58], vasculitic neuropathy [24] and spinal cord compression [15]. However, a
6 previous study found no association with NeuP [22]. It is also unclear in this study whether
7 rheumatoid arthritis is directly related to the NeuP reported. As individuals can suffer from pain in
8 multiple locations, it is possible that rheumatoid arthritis could be present in a person with NeuP in
9 another location with a different cause.

10 Another novel finding of this study is that BMI was significantly higher in people with NeuP than in
11 people with non-NeuP. Despite not being previously reported in the general population, this
12 association has been reported in specific populations with NeuP including diabetic peripheral
13 neuropathy [44] and rheumatoid arthritis [33]. Higher BMI is associated with increased risk of
14 common conditions causing NeuP including diabetes [57] and cardiovascular disease [37], whilst
15 obesity can place increased strain on the joints, exacerbating painful symptoms in rheumatoid
16 arthritis [4].

17 This study has identified some associations that conflicted with the literature. Male sex was
18 associated with increased risk of having NeuP compared to non-NeuP, whereas female sex was
19 associated with increased of having NeuP compared to NoCP. Female sex has been consistently
20 associated with NeuP when compared to non-NeuP in the literature, in both adjusted [9,50,60,62]
21 and unadjusted analysis [25,48,51]. A notable exception is a Canadian study, which also used the
22 DN4 [54]. However, a separate analysis in that study using the S-LANSS found a significant
23 association with female sex, highlighting the heterogeneity that can arise from different
24 phenotyping methods.

25 Younger age, analysed as a continuous variable, was significantly associated with NeuP. Previous
26 studies have mostly analysed age as a categorical variable and found that NeuP is more prevalent in
27 older people [9,25,32,50,54], though some have reported no association [48,51,60]. A study
28 conducted in France identified a peak prevalence of NeuP in the 50-64 year group, with the under
29 25, 25-34 and 65-74 year groups all having lower prevalences in comparison [9]. As the age range of
30 the cohort for the current study was 49-83 (Q1 = 61, Q3 = 73) years (taking into account the time
31 between initial recruitment for UK Biobank and completion of the chronic pain phenotyping survey),
32 the age group expected to have the higher prevalence of NeuP (the 50-64 year group) were amongst
33 the younger participants of UK Biobank. This could explain the findings in this study.

34 Being in a personal service, skilled trade or plant and machine operative job and not being in a
35 professional occupation, were associated with NeuP. A previous study in France found that NeuP
36 was significantly more prevalent in manual workers, farmers, retirees and other non-working
37 people, compared to those in managerial positions [9]. These are occupations in which people are
38 likely to require repetitive use of hands and feet, which could make nerve damage more likely.
39 However, it should be noted that a study in Hong Kong found no association of NeuP with manual,
40 clerical or service industry jobs when compared to professional jobs [60].

41

4.3. Strengths and Limitations

1 The main strength of this study is the NeuP sample size (n=13,747) which is more than 5 times that
2 of the largest previous study in the general population [14]. This was achieved by way of a pain
3 phenotyping survey that used validated questionnaires, such as the DN4, BPI, CPG and MNSI. This
4 will allow direct comparison with other studies of NeuP, notably DOLORisk [27,40] and the Pain in
5 Neuropathy Study (PiNS) [47]. Additionally, we conducted multivariate regression analysis on a wide
6 range of factors relating to pain, which enabled us to control for confounding factors. This compares
7 to previous studies of NeuP in the general population where regression has not been conducted
8 [14,25,32,48,51,61]. The response rate of approximately 50% compares favourably with previous
9 studies [9,14,61,62,25,32,38,48,50,51,54,60].

10 In contrast, this study also has some limitations. Our definition of NeuP relies on a self-completed
11 screening tool for NeuP, which does not meet the grading system for “probable” or “definite” NeuP
12 [19]. This includes clinical examination which is clearly not feasible in a population survey. Despite
13 this, there are a number of previous studies that have used a similar definition to the current one
14 and can be used as direct comparisons [9,25,51,54].

15 The study was cross-sectional, which means it is not possible to determine whether the relationships
16 between NeuP and the independent variables reported are causal [31]. However, for some of these
17 variables, particularly the non-modifiable ones such as age and sex, the temporal relationship can be
18 inferred. There are currently plans for UK Biobank to repeat the chronic pain survey in 2023 and this
19 will present an opportunity to conduct further longitudinal analysis to identify incidence and
20 predictors of NeuP onset.

21 A further weakness of the study is that the UK Biobank is limited to white middle-aged adults which
22 means that the cohort is not completely representative of the general population. It has also been
23 suggested that the UK Biobank under-represents people from more socioeconomically deprived
24 areas, as well as people who are obese, smoke, drink alcohol and self-report certain health
25 conditions [21]. Since NeuP has previously been associated with these health-related states, our
26 estimate of the prevalence of NeuP may be conservative [10,33,39,44]. We also found an over-
27 representation of females, younger age, lower BMI and less social deprivation in those participating
28 in the pain phenotyping survey compared to those who did not participate, suggesting an element of
29 ascertainment bias. However, it should be noted that whilst these observations reached significance
30 statistically, this may reflect the fact that the study was highly powered to detect even small
31 differences between groups.

32 Unlike in a number of previous studies [38,60,62], we were unable to analyse the treatments
33 participants had received for their pain, either through healthcare professionals or through self-
34 medication. Therefore, this should be a focus of future work. Similarly, future studies will explore the
35 wealth of genetic data that is available within UK Biobank, both to validate recent findings and to
36 potential identify novel associations [55,56].

37

4.4. Conclusions

38 This study represents the largest epidemiological study of NeuP to date and confirms that the
39 disorder is common in the general population and places a significantly greater burden on people

1 compared to those without the disorder (whether measuring those with chronic non-neuropathic
2 pain, or those reporting no chronic pain). In addition, it has identified sections of the population with
3 particular demographic and clinical characteristics that are at increased risk of having chronic NeuP,
4 some of which may be amenable to targeted prevention. These findings will be of particular interest
5 to healthcare professionals who will be able to influence clinical policy for preventing and treating
6 the disorder.

Acknowledgements

This work was supported by Diabetes UK under grant agreement 19/0005984, the European Union's Horizon 2020 research and innovation programme under grant agreement No 633491 (DOLORisk) and the MRC and Versus Arthritis funding to the PAINSTORM consortium as part of the Advanced Pain Discovery Platform (MR/W002388/1). No funding body had any role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. A.C.T is supported by Academy of Medical Sciences Starter Grant SGL022\1086, and is a Honorary Senior Research Fellow and Carnegie-Wits Diaspora Fellow at the Brain Function Research Group, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg. D.L.B and G.B are supported by the Wellcome Trust, grant reference 223149/Z/21/Z. For the purpose of open access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

Conflicts of interest

There are no conflicts of interest.

1

2 Ethics

3 Data for this study was obtained from the UK biobank for project "Risk factors for chronic pain",
4 Application ID: 49572. UK Biobank has approval from the North West Multi-centre Research Ethics
5 Committee (MREC) as a Research Tissue Bank (RTB) approval, REC reference: 21/NW/0157, IRAS
6 project ID: 299116. This approval means that researchers do not require separate ethical clearance
7 and can operate under the RTB approval.

References

- 8 [1] Abbott CA, Malik RA, Van Ross ERE, Kulkarni J, Boulton AJM. Prevalence and characteristics of
9 painful diabetic neuropathy in a large community-based diabetic population in the U.K.
10 *Diabetes Care* 2011;34:2220–2224.
- 11 [2] Aslam A, Singh J, Rajbhandari S. Prevalence of Painful Diabetic Neuropathy Using the Self-
12 Completed Leeds Assessment of Neuropathic Symptoms and Signs Questionnaire in a
13 Population with Diabetes. *Can J diabetes* 2015;39:285–295.
- 14 [3] Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira D. The specific disease burden
15 of neuropathic pain: Results of a French nationwide survey. *Pain* 2011;152:2836–2843.
- 16 [4] Bae S-C, Young J, Lee H, Lee YH. Causal association between body mass index and risk of
17 rheumatoid arthritis: A Mendelian randomization study. *Eur J Clin Invest* 2019;49:e13076.
- 18 [5] Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of
19 predominantly neuropathic origin: Validation for use in clinical and postal research. *J Pain*
20 2005;6:149–158.
- 21 [6] Biobank UK. Pain web questionnaire Version 2.0. 2021 Available:
22 https://biobank.ndph.ox.ac.uk/showcase/ukb/docs/pain_questionnaire.pdf. Accessed 12 Apr
23 2022.

- 1 [7] Blyth FM. Global burden of neuropathic pain. *Pain* 2018;159:614–617.
- 2 [8] Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J,
3 Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lantéri-Minet M, Laurent B, Mick G, Serrie A,
4 Valade D, Vicaut E. Comparison of pain syndromes associated with nervous or somatic lesions
5 and development of a new neuropathic pain diagnostic questionnaire (DN4). *Pain*
6 2005;114:29–36.
- 7 [9] Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with
8 neuropathic characteristics in the general population. *Pain* 2008;136:380–387.
- 9 [10] Bouhassira D, Letanoux M, Hartemann A. Chronic Pain with Neuropathic Characteristics in
10 Diabetic Patients: A French Cross-Sectional Study. *PLoS One* 2013;8:e74195.
- 11 [11] Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Ann Acad Med*
12 *Singapore* 1994;23:129–138.
- 13 [12] Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, Freeman R, Truini A,
14 Attal N, Finnerup NB, Eccleston C, Kalso E, Bennett DL, Dworkin RH, Raja SN. Neuropathic
15 pain. *Nat Rev Dis Prim* 2017;3:17002.
- 16 [13] Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful
17 diabetic peripheral neuropathy in type 2 diabetes. *Diabetes Care* 2006;29:1518–1522.
- 18 [14] DiBonaventura MD, Sadosky A, Concialdi K, Hopps M, Kudel I, Parsons B, Cappelleri JC,
19 Hlavacek P, Alexander AH, Stacey BR, Markman JD, Farrar JT. The prevalence of probable
20 neuropathic pain in the US: results from a multimodal general-population health survey. *J*
21 *Pain Res* 2017;10:2525–2538.
- 22 [15] Dreyer SJ, Boden SD. Natural history of rheumatoid arthritis of the cervical spine. *Clin Orthop*
23 *Relat Res* 1999;366:98–106. doi:10.1097/00003086-199909000-00013.
- 24 [16] Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step
25 quantitative clinical and electrophysiological assessment for the diagnosis and staging of
26 diabetic neuropathy. *Diabetes Care* 1994;17:1281–1289.
- 27 [17] Fernandes GS, Valdes AM, Walsh DA, Zhang W, Doherty M. Neuropathic-like knee pain and
28 associated risk factors: A cross-sectional study in a UK community sample. *Arthritis Res Ther*
29 2018;20:215.
- 30 [18] Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M,
31 Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice ASC, Rowbotham M,
32 Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: A
33 systematic review and meta-analysis. *Lancet Neurol* 2015;14:162–173.
- 34 [19] Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DLH, Bouhassira D, Cruccu G,
35 Freeman R, Hansson P, Nurmikko T, Raja SN, Rice ASC, Serra J, Smith BH, Treede RD, Jensen
36 TS. Neuropathic pain: An updated grading system for research and clinical practice. *Pain*
37 2016;157:1599–1606.
- 38 [20] Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to
39 identify neuropathic components in patients with back pain. *Curr Med Res Opin*
40 2006;22:1911–1920.
- 41 [21] Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R, Allen NE.
42 Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank
43 Participants With Those of the General Population. *Am J Epidemiol* 2017;186:1026–1034.
- 44 [22] Garip Y, Eser F, Kiliçarslan A, Bodur H. Prevalence of Neuropathic Pain in Rheumatic

- 1 Disorders: Association With Disease Activity, Functional Status and Quality of Life. *Arch*
2 *Rheumatol* 2015;30:231–237.
- 3 [23] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and
4 national incidence, prevalence, and years lived with disability for 354 diseases and injuries for
5 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of
6 Disease Study 2017. *Lancet* 2018;392:1789–1858.
- 7 [24] Gwathmey KG, Burns TM, Collins MP, Dyck PJB. Vasculitic neuropathies. *Lancet Neurol*
8 2014;13:67–82. doi:10.1016/S1474-4422(13)70236-9.
- 9 [25] Harifi G, Amine M, Ait Ouazar M, Boujemaoui A, Ouilki I, Rekkab I, Belkhou A, El Bouchti I,
10 Niamane R, El Hassani S. Prevalence of chronic pain with neuropathic characteristics in the
11 Moroccan general population: a national survey. *Pain Med* 2013;14:287–292.
- 12 [26] Hébert HL, Colvin LA, Smith BH. The impact of gabapentinoid and opioid prescribing practices
13 on drug deaths: an epidemiological perspective. *Pain Manag* 2022;12:397–400.
- 14 [27] Hébert HL, Veluchamy A, Baskozos G, Fardo F, Van Ryckeghem DML, Pascal MM V., Jones C,
15 Milburn K, Pearson ER, Crombez G, Bennett DLH, Meng W, Palmer CNA, Smith BH. Cohort
16 profile: DOLORisk Dundee: a longitudinal study of chronic neuropathic pain. *BMJ Open*
17 2021;11:e042887.
- 18 [28] Van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general
19 population: A systematic review of epidemiological studies. *Pain* 2014;155:654–662.
- 20 [29] Van Hecke O, Kamerman PR, Attal N, Baron R, Bjornsdottir G, Bennett DLH, Bennett MI,
21 Bouhassira D, Diatchenko L, Freeman R, Freynhagen R, Haanpää M, Jensen TS, Raja SN, Rice
22 ASC, Seltzer Z, Thorgeirsson TE, Yarnitsky D, Smith BH. Neuropathic pain phenotyping by
23 international consensus (NeuroPPIC) for genetic studies: A NeuPSIG systematic review, Delphi
24 survey, and expert panel recommendations. *Pain* 2015;156:2337–2353.
- 25 [30] Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonse G, Badia X. Development
26 and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res*
27 2011;20:1727–1736.
- 28 [31] Imagama S, Ando K, Kobayashi K, Nakashima H, Seki T, Hamada T, Machino M, Ota K, Tanaka
29 S, Morozumi M, Kanbara S, Ito S, Ishiguro N, Hasegawa Y. Risk Factors for Neuropathic Pain in
30 Middle-Aged and Elderly People: A Five-Year Longitudinal Cohort in the Yakumo Study. *Pain*
31 *Med* 2020;21:1604–1610.
- 32 [32] Inoue S, Taguchi T, Yamashita T, Nakamura M, Ushida T. The prevalence and impact of
33 chronic neuropathic pain on daily and social life: A nationwide study in a Japanese
34 population. *Eur J Pain* 2017;21:727–737.
- 35 [33] Ito S, Kobayashi D, Murasawa A, Narita I, Nakazono K. An Analysis of the Neuropathic Pain
36 Components in Rheumatoid Arthritis Patients. *Intern Med* 2018;57:479–485.
- 37 [34] Koop SMW, ten Klooster PM, Vonkeman HE, Steunebrink LMM, van de Laar MAFJ.
38 Neuropathic-like pain features and cross-sectional associations in rheumatoid arthritis.
39 *Arthritis Res Ther* 2015;17:237.
- 40 [35] Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity
41 measure. *J Gen Intern Med* 2001;16:606–613.
- 42 [36] Krupp LB, Larocca NG, Muir Nash J, Steinberg AD. The Fatigue Severity Scale: Application to
43 Patients With Multiple Sclerosis and Systemic Lupus Erythematosus. *Arch Neurol*
44 1989;46:1121–1123.

- 1 [37] Larsson SC, Bäck M, Rees JMB, Mason AM, Burgess S. Body mass index and body composition
2 in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study.
3 *Eur Heart J* 2020;41:221–226.
- 4 [38] De Moraes Vieira ÉB, Garcia JBS, Da Silva AAM, Mualem Araújo RLT, Jansen RCS. Prevalence,
5 characteristics, and factors associated with chronic pain with and without neuropathic
6 characteristics in São Luís, Brazil. *J Pain Symptom Manage* 2012;44:239–251.
- 7 [39] Parruti G, Tontodonati M, Rebuzzi C, Polilli E, Sozio F, Consorte A, Agostinone A, Di Masi F,
8 Congedo G, D’Antonio D, Granchelli C, D’Amario C, Carunchio C, Pippa L, Manzoli L, Volpi A.
9 Predictors of pain intensity and persistence in a prospective Italian cohort of patients with
10 herpes zoster: Relevance of smoking, trauma and antiviral therapy. *BMC Med* 2010;8:58.
- 11 [40] Pascal MM V, Themistocleous AC, Baron R, Binder A, Bouhassira D, Crombez G, Finnerup NB,
12 Gierthmühlen J, Granovsky Y, Groop L, Hebert HL, Jensen TS, Johnsen K, McCarthy MI, Meng
13 W, Palmer CNA, Rice ASC, Serra J, Solà R, Yarnitsky D, Smith BH, Attal N, Bennett DLH.
14 DOLORisk: study protocol for a multi-centre observational study to understand the risk
15 factors and determinants of neuropathic pain. *Wellcome open Res* 2018;3:63.
16 doi:10.12688/wellcomeopenres.14576.2.
- 17 [41] Smith BH, Campbell A, Linksted P, Fitzpatrick B, Jackson C, Kerr SM, Deary IJ, MacIntyre DJ,
18 Campbell H, McGilchrist M, Hocking LJ, Wisely L, Ford I, Lindsay RS, Morton R, Palmer CNA,
19 Dominiczak AF, Porteous DJ, Morris AD. Cohort profile: Generation Scotland: Scottish family
20 health study (GS: SFHS). The study, its participants and their potential for genetic research on
21 health and illness. *Int J Epidemiol* 2013;42:689–700.
- 22 [42] Smith BH, Campbell H, Blackwood D, Connell J, Connor M, Deary IJ, Dominiczak AF, Fitzpatrick
23 B, Ford I, Jackson C, Haddow G, Kerr S, Lindsay R, McGilchrist M, Morton R, Murray G, Palmer
24 CNA, Pell JP, Ralston SH, St. Clair D, Sullivan F, Watt G, Wolf R, Wright A, Porteous D, Morris
25 AD. Generation Scotland: The Scottish Family Health Study; a new resource for researching
26 genes and heritability. *BMC Med Genet* 2006;7:74.
- 27 [43] Smith BH, Hébert HL, Veluchamy A. Neuropathic pain in the community: prevalence, impact,
28 and risk factors. *Pain* 2020;161:S127–S137.
- 29 [44] Spallone V, Morganti R, D’Amato C, Cacciotti L, Fedele T, Maiello MR, Marfia G. Clinical
30 correlates of painful diabetic neuropathy and relationship of neuropathic pain with
31 sensorimotor and autonomic nerve function. *Eur J Pain* 2011;15:153–160.
- 32 [45] Stocks J, Tang NK, Walsh DA, Warner SC, Harvey HL, Jenkins W, Abhishek A, Doherty M,
33 Valdes AM. Bidirectional association between disturbed sleep and neuropathic pain
34 symptoms: a prospective cohort study in post-total joint replacement participants What did
35 the researchers do and find? *J Pain Res* 2018;11:1087–1093.
- 36 [46] Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J,
37 Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T, Collins
38 R. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of
39 Complex Diseases of Middle and Old Age. *PLoS Med* 2015;12:e1001779.
- 40 [47] Themistocleous AC, Ramirez JD, Shillo PR, Lees JG, Selvarajah D, Orengo C, Tesfaye S, Rice
41 ASC, Bennett DLH. The Pain in Neuropathy Study (PiNS): a cross-sectional observational study
42 determining the somatosensory phenotype of painful and painless diabetic neuropathy. *Pain*
43 2016;157:1132–1145. doi:10.1097/J.PAIN.0000000000000491.
- 44 [48] Torrance N, Ferguson JA, Afolabi E, Bennett MI, Serpell MG, Dunn KM, Smith BH. Neuropathic
45 pain in the community: more under-treated than refractory? *Pain* 2013;154:690–699.

- 1 [49] Torrance N, Lawson KD, Afolabi E, Bennett MI, Serpell MG, Dunn KM, Smith BH. Estimating
2 the burden of disease in chronic pain with and without neuropathic characteristics: Does the
3 choice between the EQ-5D and SF-6D matter? *Pain* 2014;155:1996–2004.
- 4 [50] Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly
5 neuropathic origin. Results from a general population survey. *J pain* 2006;7:281–289.
- 6 [51] Toth C, Lander J, Wiebe S. The prevalence and impact of chronic pain with neuropathic pain
7 symptoms in the general population. *Pain Med* 2009;10:918–929.
- 8 [52] Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R,
9 Nurmikko T, Serra J. Neuropathic pain: Redefinition and a grading system for clinical and
10 research purposes. *Neurology* 2008;70:1630–1635.
- 11 [53] Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB,
12 First MB, Giamberardino MA, Kaasa S, Korwisi B, Kosek E, Lavand’Homme P, Nicholas M,
13 Perrot S, Scholz J, Schug S, Smith BH, Svensson P, Vlaeyen JWS, Wang SJ. Chronic pain as a
14 symptom or a disease: The IASP Classification of Chronic Pain for the International
15 Classification of Diseases (ICD-11). *Pain* 2019;160:19–27.
- 16 [54] VanDenKerkhof EG, Mann EG, Torrance N, Smith BH, Johnson A, Gilron I. An Epidemiological
17 Study of Neuropathic Pain Symptoms in Canadian Adults. *Pain Res Manag*
18 2016;2016:9815750.
- 19 [55] Veluchamy A, Hébert HL, Meng W, Palmer CNA, Smith BH. Systematic review and meta-
20 analysis of genetic risk factors for neuropathic pain. *Pain* 2018;159:825–848.
- 21 [56] Veluchamy A, Hébert HL, Van Zuydam NR, Pearson ER, Campbell A, Hayward C, Meng W,
22 McCarthy MI, Bennett DLH, Palmer CNA, Smith BH. Association of Genetic Variant at
23 Chromosome 12q23.1 With Neuropathic Pain Susceptibility. *JAMA Netw Open*
24 2021;4:e2136560.
- 25 [57] Wainberg M, Mahajan A, Kundaje A, McCarthy MI, Ingelsson E, Sinnott-Armstrong N, Rivas
26 MA. Homogeneity in the association of body mass index with type 2 diabetes across the UK
27 Biobank: A Mendelian randomization study. *PLOS Med* 2019;16:e1002982.
- 28 [58] Wiberg A, Smillie RW, Dupré S, Schmid AB, Bennett DL, Furniss D. Replication of
29 epidemiological associations of carpal tunnel syndrome in a UK population-based cohort of
30 over 400,000 people. *J Plast Reconstr Aesthetic Surg* 2022;75:1034.
- 31 [59] Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ,
32 Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria
33 for fibromyalgia and measurement of symptom severity. *Arthritis Care Res (Hoboken)*
34 2010;62:600–610. doi:10.1002/ACR.20140.
- 35 [60] Wong SSC, Choi SW, Cheung CW. A comparison of chronic pain with and without neuropathic
36 characteristics in a Hong Kong Chinese population: An analysis of pain related outcomes and
37 patient help seeking behaviour. *PLoS One* 2018;13:e0204054.
- 38 [61] Yawn BP, Wollan PC, Weingarten TN, Watson JC, Hooten WM, Melton LJ. The prevalence of
39 neuropathic pain: Clinical evaluation compared with screening tools in a community
40 population. *Pain Med* 2009;10:586.
- 41 [62] Zghoul N, Ross EL, Edwards RR, Ahmed A, Jamison RN. Prevalence of chronic pain with
42 neuropathic characteristics: a randomized telephone survey among medical center patients
43 in Kuwait. *J Pain Res* 2017;10:679–687.

Figure legends

Figure 1

Demographics of participants with chronic NeuP, Non-Neup and NoCP. A: Boxplots show the age of participants when questionnaires were completed for each group. Notched line represents the median. B: Stacked bar plots show the sex distribution across the three groups. C: Stacked bar plots show the ethnic background distribution across the three groups. D: Boxplots show the BMI of participants across the three groups. Omnibus ANOVAs are labelled in the plot and are followed-up by t-tests between groups. P.value < 0.001 is coded as ***, p.value < 0.01 is coded as ** 0.01, p.value < 0.05 is coded as *. Post-hoc tests are shown in supplementary figure 1.

Figure 2

Socio-economic status of participants with chronic NeuP, Non-Neup and NoCP. A: Dotplot shows the employment status of participants for each group. The group is colour coded, the respective percentage is coded in the size of the dot. B: Dotplot shows the occupation of participants for each group. C: Boxplots show the index of multiple deprivations across the three groups. Omnibus ANOVAs are labelled in the plot and are followed-up by t-tests between groups. P.value < 0.001 is coded as ***, p.value < 0.01 is coded as ** 0.01, p.value < 0.05 is coded as *. Post-hoc tests are shown in supplementary figure 2.

Figure 3

Pain rating and location of the most bothersome pain. A: Boxplots show the pain rating for the self-reported location of the most bothersome pain for both painful groups, NeuP vs Non-NeuP. B: Dotplot shows the frequencies for the self-reported location of the most bothersome pain for the two painful groups. Rates are coded in the size of the dot. P.value < 0.001 is coded as ***, p.value < 0.01 is coded as ** 0.01, p.value < 0.05 is coded as *.

Figure 4

The impact of pain in quality of life. A: Boxplots show the EQ5D index across the three groups. B: Boxplots show the EQ5D for both painful groups across all locations reported as the ones having the most bothersome pain. Omnibus ANOVAs are labelled in the plot and are followed-up by t-tests between groups. P.value < 0.001 is coded as ***, p.value < 0.01 is coded as ** 0.01, p.value < 0.05 is coded as *. Post-hoc tests are shown in supplementary figure 3.

Figure 5

Frequencies of diseases across the three groups. The rates are coded in the size of the dot. Group allocation is colour coded. Post-hoc tests are shown in supplementary figure 4.

Figure 6

Pain rating and DN4 scores. A: Boxplots show the distribution of pain ratings for the most bothersome locations across DN4 scores for both painful groups. Group is colour coded. B: Boxplots show the DN4 score for all different locations of self-reported most bothersome pain. C: DN4 scores for people with and without pain in both feet, Omnibus Kruskal-Wallis tests are labelled in the plot. P.value < 0.001 is coded as ***, p.value < 0.01 is coded as ** 0.01, p.value < 0.05 is coded as *.

Figure 7





Intensity of pain versus participant characteristics. A: Boxplots show the distribution BMI for different self-reported pain intensities for the most bothersome location. B: Boxplots show the EQ5D index across self-reported pain intensities for the most bothersome locations. C: Frequencies of employment status across self-reported pain intensities for the most bothersome locations. D: Index of multiple deprivations or different self-reported pain intensities for the most bothersome location. Notched lines represent the median.

Figure 8


Coefficient estimates of the multinomial logit model. Dots represent the exponentiated coefficient estimates, i.e. odds ratios, and lines show the 95% confidence interval for all terms with an one-way ANOVA p.value < 0.05. Odds ratios are calculated for NeuP and Non-NeuP against the reference level NoCP.

Figure 9


Coefficient estimates of the binomial logit model for the two painful groups. Dots represent the exponentiated coefficient estimates, i.e. odds ratios, and lines show the 95% confidence interval for all terms with an one-way ANOVA p.value < 0.05. Odds ratios are calculated for NeuP against the reference level Non-NeuP (constituting the sum of Non-NeuP and NoCP). The p.value is colour coded.




A



B




C




A

■ Chronic_Non_Neuropathic_Pain
 ■ Chronic_Neuropathic_Pain


**B**


A

■ No_Chronic_Pain
 ■ Chronic_Non_Neuropathic_Pain
 ■ Chronic_Neuropathic_Pain

**B**



■ Chronic_Non_Neuropathic_Pain
 ■ Chronic_Neuropathic_Pain





A

Chronic_Non_Neuropathic_Pain Chronic_Neuropathic_Pain

**B****C**